Leukemia Therapeutics Market Research Report – Global Forecast till 2027

Leukemia Therapeutics Market Research Report: by Type (Chemotherapy, Biological, Targeted, Radiation), by Application (Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia) - Global Forecast Till 2027

ID: MRFR/HC/5956-HCR | February 2021 | Region: Global | 110 pages

Please note that the assessment period of report has been updated from 2018-2023 to 2020-2027. Cordially fill the sample form for updated data.

Market Scenario


Global leukemia therapeutics market is expected to grow significantly over the forecast period. It is anticipated that the market held value of USD 10.7 billion in 2017 and is projected to grow at a CAGR of 5.3% over the forecast period.


Leukemia is blood cancer which most commonly in adults and children. Acute lymphocytic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia are the major types of the leukemia. leukemia therapeutics are used in treating the leukemia.


The factors such as innovative therapies to drive the market for leukemia, increase prevalence of leukemia, and increasing older population are expected to propel the growth of the market. However, high cost required for the development of new therapeutics hamper the market growth over the forecast period.


Segmentation


The global leukemia therapeutics market has been segmented into type, applications, and region.


Based on type, leukemia therapeutics market is segmented into chemotherapy, biological therapy, targeted therapy, radiation therapy, and stem cell transplant. The chemotherapy segment is expected to account for the largest share segment of the market in 2017. Chemotherapy segment further sub segmented into alkylating agents, antimetabolites, antitumor antibiotics, and others.


Based on applications, leukemia therapeutics market is segmented into acute lymphocytic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, and others.


The leukemia therapeutics market segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The leukemia therapeutics market in the Americas further segmented into North America and Latin America, with the North American market divided into the US and Canada.


The European leukemia therapeutics market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.


The leukemia therapeutics market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The leukemia therapeutics market in the Middle East & Africa segmented into the Middle East and Africa.


Regional Market Summary


Global Leukemia Therapeutics Market Share (%), by Region, 2017


Leukemia Therapeutics Market


Source: Annual Reports and Sec filings


Geographically, the Americas is anticipated to dominate the global leukemia therapeutics market owing to a well-established player, innovative therapies to drive the market for leukemia, increase prevalence of leukemia, and increasing older population.


Europe is expected to hold the second largest position in the global leukemia therapeutics market. The market growth in this region is attributed to increase prevalence of leukemia.


The leukemia therapeutics market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region.


The Middle East & Africa has the least share of the leukemia therapeutics market.


Global Leukemia Therapeutics Market, by Treatment Type



  • Chemotherapy

    • Alkylating Agents

    • Antimetabolites

    • Antitumor Antibiotics

    • Others



  • Biological Therapy

  • Targeted Therapy

  • Radiation Therapy

  • Stem Cell Transplant

  • Others


Global Leukemia Therapeutics Market, by Application



  • Acute Lymphocytic Leukemia

  • Acute Myelogenous Leukemia

  • Chronic Lymphocytic Leukemia

  • Chronic Myelogenous Leukemia

  • Others


Global Leukemia Therapeutics Market, by Region



  • Americas

    • North America

      • US

      • Canada



    • Latin America



  • Europe

    • Western Europe

      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe



    • Eastern Europe



  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific



  • The Middle East & Africa

    • Middle East

    • Africa




Global Leukemia Therapeutics Market, by Key Players



  • Eisai Co., Ltd (Japan)

  • Novartis AG (Switzerland)

  • Pfizer Inc. (US)

  • GlaxoSmithKline plc (UK)

  • Bristol-Myers Squibb Company (US)

  • Hoffmann-La Roche AG (Switzerland)

  • Sanofi S.A. (France)

  • Teva Pharmaceutical Industries Ltd (Israel)

  • Amgen Inc (US)

  • Takeda Pharmaceutical Company Ltd (Japan)


Intended Audience



  • Leukemia Therapeutics Manufacturers and Vendors

  • Research Organization

  • Various Research and Consulting Firms

  • Cancer Organization and Association



Frequently Asked Questions (FAQ) :


The leukemia therapeutics market is projected to grow at a 5.3% CAGR between 2018-2023.

The Americas is expected to dominate the leukemia therapeutics market.

The acute lymphocytic leukemia segment will dominate the leukemia therapeutics market.

Increasing prevalence of leukemia, increasing older population, and availability of innovative therapies are boosting market growth.

High cost may restrict the growth of the leukemia therapeutics market.

Table of Contents:


Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

Chapter 3. Research Methodology

3.1. Introduction

3.2. Primary Research

3.3. Secondary Research

3.4. Market Application Estimation

Chapter 4. Market Dynamics

4.1. Drivers

4.2. Restraints

4.3. Opportunities

4.4. Challenges

Chapter 5. Market Factor Analysis

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

5.3. Investment Feasibility Analysis

5.4. Pricing Analysis

Chapter 6. Global Leukemia Therapeutics Market, by Type

6.1. Introduction

6.2. Chemotherapy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.2.1. Alkylating Agents

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.2.2. Antimetabolites

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.2.3. Antitumor Antibiotics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.2.4. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3. Biological Therapy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4. Targeted Therapy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.5. Radiation Therapy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.6. Stem Cell Transplant

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 7. Global Leukemia Therapeutics Market, by Application

7.1. Introduction

7.2. Acute Lymphocytic Leukemia

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3. Acute Myelogenous Leukemia

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.4. Chronic Lymphocytic Leukemia

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.5. Chronic Myelogenous Leukemia.

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.6. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 8. Global Leukemia Therapeutics Market, by Region

8.1. Introduction

8.2. Americas

8.2.1. North America

8.2.1.1. US

8.2.1.2. Canada

8.2.2. Latin America

8.3. Europe

8.3.1. Western Europe

8.3.1.1. Germany

8.3.1.2. France

8.3.1.3. Italy

8.3.1.4. Spain

8.3.1.5. UK

8.3.1.6. Rest of Western Europe

8.3.2. Eastern Europe

8.4. Asia-Pacific

8.4.1. Japan

8.4.2. China

8.4.3. India

8.4.4. Australia

8.4.5. South Korea

8.4.6. Rest of Asia-Pacific

8.5. Middle East & Africa

8.5.1. Middle East

8.5.2. Africa

Chapter 9. Company Landscape

9.1. Introduction

9.2. Market Share Analysis

9.3. Key Developments & Strategies

Chapter 10. Company Profiles

10.1. EISAI CO., LTD

10.1.1. Company Overview

10.1.2. Type Overview

10.1.3. Financials Overview

10.1.4. Key Developments

10.1.5. SWOT Analysis

10.1.6. Key Strategies

10.2. Novartis AG

10.2.1. Company Overview

10.2.2. Type Overview

10.2.3. Financials Overview

10.2.4. Key Developments

10.2.5. SWOT Analysis

10.2.6. Key Strategies

10.3. PFIZER INC.

10.3.1. Company Overview

10.3.2. Type Overview

10.3.3. Financials Overview

10.3.4. Key Developments

10.3.5. SWOT Analysis

10.3.6. Key Strategies

10.4. GLAXOSMITHKLINE PLC

10.4.1. Company Overview

10.4.2. Type Overview

10.4.3. Financials Overview

10.4.4. Key Developments

10.4.5. SWOT Analysis

10.4.6. Key Strategies

10.5. Bristol-Myers Squibb Company

10.5.1. Company Overview

10.5.2. Type Overview

10.5.3. Financials Overview

10.5.4. Key Developments

10.5.5. SWOT Analysis

10.5.6. Key Strategies

10.6. F. Hoffmann-La Roche AG

10.6.1. Company Overview

10.6.2. Type Overview

10.6.3. Financials Overview

10.6.4. Key Developments

10.6.5. SWOT Analysis

10.6.6. Key Strategies

10.7. Sanofi S.A.

10.7.1. Company Overview

10.7.2. Type Overview

10.7.3. Financials Overview

10.7.4. Key Developments

10.7.5. SWOT Analysis

10.7.6. Key Strategies

10.8. Teva Pharmaceutical Industries Ltd.

10.8.1. Company Overview

10.8.2. Type Overview

10.8.3. Financials Overview

10.8.4. Key Developments

10.8.5. SWOT Analysis

10.8.6. Key Strategies

10.9. Amgen Inc.

10.9.1. Company Overview

10.9.2. Type Overview

10.9.3. Financials Overview

10.9.4. Key Developments

10.9.5. SWOT Analysis

10.9.6. Key Strategies

10.10. Takeda Pharmaceutical Company Ltd

10.10.1. Company Overview

10.10.2. Type Overview

10.10.3. Financials Overview

10.10.4. Key Developments

10.10.5. SWOT Analysis

10.10.6. Key Strategies

10.11. Others

Chapter 11. MRFR Conclusion

11.1. Key Findings

11.1.1. From CEO’s View point

11.1.2. Unmet Needs of the Market

11.2. Key Companies to Watch

11.3. Predictions for the Leukemia Therapeutics Industry

Chapter 12. Appendix

LIST OF TABLES

Table 1. Global Leukemia Therapeutics Market Synopsis, 2020-2027

Table 2. Global Leukemia Therapeutics Market Estimates and Forecast, 2020-2027 (USD Million)

Table 3. Global Leukemia Therapeutics Market, by Region, 2020-2027 (USD Million)

Table 4. Global Leukemia Therapeutics Market, by Type, 2020-2027 (USD Million)

Table 5. Global Leukemia Therapeutics Market, by Application, 2020-2027 (USD Million)

Table 6. North America: Leukemia Therapeutics Market, by Type, 2020-2027 (USD Million)

Table 7. North America: Leukemia Therapeutics Market, by Application, 2020-2027 (USD Million)

Table 8. US: Leukemia Therapeutics Market, by Type, 2020-2027 (USD Million)

Table 9. US: Leukemia Therapeutics Market, by Application, 2020-2027 (USD Million)

Table 10. Canada: Leukemia Therapeutics Market, by Type, 2020-2027 (USD Million)

Table 11. Canada: Leukemia Therapeutics Market, by Application, 2020-2027 (USD Million)

Table 12. Latin America: Leukemia Therapeutics Market, by Type, 2020-2027 (USD Million)

Table 13. Latin America: Leukemia Therapeutics Market, by Application, 2020-2027 (USD Million)

Table 14. Europe: Leukemia Therapeutics Market, by Type, 2020-2027 (USD Million)

Table 15. Europe: Leukemia Therapeutics Market, by Application, 2020-2027 (USD Million)

Table 16. Western Europe: Leukemia Therapeutics Market, by Type, 2020-2027 (USD Million)

Table 17. Western Europe: Leukemia Therapeutics Market, by Application, 2020-2027 (USD Million)

Table 18. Eastern Europe: Leukemia Therapeutics Market, by Type, 2020-2027 (USD Million)

Table 19. Eastern Europe: Leukemia Therapeutics Market, by Application, 2020-2027 (USD Million)

Table 20. Asia-Pacific: Leukemia Therapeutics Market, by Type, 2020-2027 (USD Million)

Table 21. Asia-Pacific: Leukemia Therapeutics Market, by Application, 2020-2027 (USD Million)

Table 22. Middle East & Africa: Leukemia Therapeutics Market, by Type, 2020-2027 (USD Million)

Table 23. Middle East & Africa: Leukemia Therapeutics Market, by Application, 2020-2027 (USD Million)

LIST OF FIGURES

Figure 1. Research Process

Figure 2. Segmentation for Global Leukemia Therapeutics Market

Figure 3. Market Dynamics for Global Leukemia Therapeutics Market

Figure 4. Global Leukemia Therapeutics Market Share, by Type, 2020

Figure 5. Global Leukemia Therapeutics Market Share, by Application, 2020

Figure 6. Global Leukemia Therapeutics Market Share, by Region, 2020

Figure 7. North America: Leukemia Therapeutics Market Share, by Country, 2020

Figure 8. Europe: Leukemia Therapeutics Market Share, by Country, 2020

Figure 9. Asia-Pacific: Leukemia Therapeutics Market Share, by Country, 2020

Figure 10. Middle East & Africa: Leukemia Therapeutics Market Share, by Country, 2020

Figure 11. Global Leukemia Therapeutics Market: Company Share Analysis, 2020 (%)

Figure 12. EISAI CO., LTD: Key Financials

Figure 13. EISAI CO., LTD: Segmental Revenue

Figure 14. EISAI CO., LTD: Geographical Revenue

Figure 15. Novartis AG: Key Financials

Figure 16. Novartis AG: Segmental Revenue

Figure 17. Novartis AG: Geographical Revenue

Figure 18. PFIZER INC.: Key Financials

Figure 19. PFIZER INC.: Segmental Revenue

Figure 20. PFIZER INC.: Geographical Revenue

Figure 21. GLAXOSMITHKLINE PLC: Key Financials

Figure 22. GLAXOSMITHKLINE PLC: Segmental Revenue

Figure 23. GLAXOSMITHKLINE PLC: Geographical Revenue

Figure 24. Bristol-Myers Squibb Company: Key Financials

Figure 25. Bristol-Myers Squibb Company: Segmental Revenue

Figure 26. Bristol-Myers Squibb Company: Geographical Revenue

Figure 27. F. Hoffmann-La Roche AG: Key Financials

Figure 28. F. Hoffmann-La Roche AG: Segmental Revenue

Figure 29. F. Hoffmann-La Roche AG: Geographical Revenue

Figure 30. Sanofi S.A.: Key Financials

Figure 31. Sanofi S.A.: Segmental Revenue

Figure 32. Sanofi S.A.: Geographical Revenue

Figure 33. Teva Pharmaceutical Industries Ltd.: Key Financials

Figure 34. Teva Pharmaceutical Industries Ltd.: Segmental Revenue

Figure 35. Teva Pharmaceutical Industries Ltd.: Geographical Revenue

Figure 36. Amgen Inc.: Key Financials

Figure 37. Amgen Inc.: Segmental Revenue

Figure 38. Amgen Inc.: Geographical Revenue

Figure 39. Takeda Pharmaceutical Company Ltd: Key Financials

Figure 40. Takeda Pharmaceutical Company Ltd: Segmental Revenue

Figure 41. Takeda Pharmaceutical Company Ltd: Geographical Revenue



This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.